Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Irinotecan in recurrent high-grade gliomas
NCT00393094Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2006
- Primary completion
- Jan 2010
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in glioma, sponsored by National Cancer Institute. Started Sep 2006; status: terminated.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
glioma
Beyond the preview
Go deeper on NCT00393094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00393094.